Moderna (MRNA) Stock Slides 6% Premarket Despite Revenue Gain Amid $782M Loss

Key Highlights

Table of Contents

Moderna stock declined 6% in premarket session following Q2 earnings release
Quarterly revenue increased marginally to $145 million year-over-year
Net loss improved to $782 million compared to $825 million in prior year
Company reduces 2026 operational and R&D expense guidance by approximately $200 million
Phase 3 norovirus vaccine candidate fails to achieve interim efficacy benchmark
FDA regulatory decisions expected August 5 for seasonal influenza vaccine hopefuls

Shares of Moderna (MRNA) declined 6.09% to $54.39 during premarket hours following the biotechnology company’s second-quarter earnings announcement. While the firm posted modest revenue growth and reduced its operating loss, investors reacted negatively to a clinical trial disappointment in its norovirus vaccine program.

Moderna, Inc., MRNA

Second Quarter Shows Revenue Growth Alongside Expense Management

Moderna delivered second-quarter revenue totaling $145 million, representing a slight increase from $142 million in the comparable 2024 period. Domestic operations generated $87 million while overseas markets accounted for $58 million. Revenue performance benefited from United Kingdom distribution agreements and partnership revenues, which helped compensate for softer COVID-19 vaccine demand in various territories.

The company’s cost of sales decreased 22% year-over-year to $93 million, reflecting enhanced production efficiency. This figure incorporated $41 million related to inventory reserves and $23 million attributed to underutilized manufacturing capacity. Research and development expenditures dropped 7% to $651 million as the company wound down certain development programs.

Selling, general, and administrative costs fell 6% to $216 million due to disciplined cost management initiatives throughout the organization. The biotechnology firm recorded a net loss of $782 million for the quarter, an improvement from the $825 million loss reported in the year-ago period. On a per-share basis, the loss contracted to $1.97 from $2.13.

Company Refines Financial Outlook and Lowers Expense Projections

The Cambridge-based company reaffirmed its revenue growth objective of up to 10% for fiscal year 2026. Management anticipates balanced contributions between domestic and international operations. Additionally, the firm projects approximately 55% of second-half revenues will materialize during the third quarter.

Moderna revised downward its anticipated cost of sales to $1.7 billion from a previous estimate of $1.8 billion. Research and development spending expectations were similarly trimmed to $2.9 billion from $3.0 billion. Selling, general, and administrative expenses are projected to hold steady around $1.0 billion.

The company’s cash position and investment holdings totaled $6.9 billion as of June 30, declining from $7.5 billion at the end of the first quarter. This figure preceded a $950 million payment made in July to resolve litigation. Management forecasts year-end cash balances ranging between $4.7 billion and $5.2 billion.

Clinical Pipeline Produces Mixed Development Outcomes

Moderna broadened commercial distribution through fresh supply agreements and regulatory clearances spanning European, Asian, and Latin American territories. The European Commission finalized procurement arrangements for up to 24 million doses of mRESVIA across six member states. Health authorities granted marketing authorization for mRESVIA and mNEXSPIKE in four additional countries.

The Food and Drug Administration established August 5 as the target action date for reviewing seasonal influenza candidate mRNA-1010. The company simultaneously awaits a regulatory determination on mFLUSIVA, which could become its fifth commercialized product. European health authorities previously granted approval for mCOMBRIAX, a combination flu and COVID-19 vaccine, for regional distribution.

The company’s Phase 3 clinical trial evaluating a norovirus vaccine candidate did not achieve predefined success criteria during a planned interim analysis. The study continues under blinded conditions, with management planning to recruit an additional patient cohort. In separate pipeline developments, clinical data readouts for melanoma and propionic acidemia programs are anticipated before the conclusion of 2026.

✨ Limited Time Offer